We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$717M
AUM Growth
+$143M
Cap. Flow
+$179M
Cap. Flow %
24.96%
Top 10 Hldgs %
42.64%
Holding
176
New
63
Increased
14
Reduced
29
Closed
31

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$15.9M
2
RCUS icon
Arcus Biosciences
RCUS
+$9.44M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.44M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.12M
5
BPMC
Blueprint Medicines
BPMC
+$8.44M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20.7M
2
SLNO
Soleno Therapeutics
SLNO
+$10.7M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.35M
4
NUVL
Nuvalent
NUVL
+$8.24M
5
AMGN icon
Amgen
AMGN
+$8.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANVS icon
151
PUT
Annovis Bio
ANVS
$74.4M
– –
-5,517
Closed -$3.18M
ARE icon
152
PUT
Alexandria Real Estate Equities
ARE
$8.97B
– –
-733
Closed -$8.57M
ARQT icon
153
Arcutis Biotherapeutics
ARQT
$3.36B
– –
-489,642
Closed -$4.55M
JBIO
154
CALL
Jade Biosciences
JBIO
$1.2B
– –
-29
Closed -$166K
AZN icon
155
CALL
AstraZeneca
AZN
$263B
– –
-546
Closed -$8.52M
BBIO icon
156
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-6,000
Closed -$15.2M
BCLI
157
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-6,016
Closed -$30.5K
CORT icon
158
CALL
Corcept Therapeutics
CORT
$12.4B
– –
-1,860
Closed -$6.04M
GPCR icon
159
CALL
Structure Therapeutics
GPCR
$3.41B
– –
-290
Closed -$1.14M
GPCR icon
160
PUT
Structure Therapeutics
GPCR
$3.41B
– –
-290
Closed -$1.14M
IMVT icon
161
Immunovant
IMVT
$7.93B
– –
-276,925
Closed -$8.17M
INSM icon
162
CALL
Insmed
INSM
$21.4B
– –
-5,070
Closed -$34M
INSM icon
163
PUT
Insmed
INSM
$21.4B
– –
-709
Closed -$4.75M
NBIX icon
164
CALL
Neurocrine Biosciences
NBIX
$16.8B
– –
-1,000
Closed -$13.8M
NBIX icon
165
Neurocrine Biosciences
NBIX
$16.8B
– –
-40,000
Closed -$5.51M
PRAX icon
166
CALL
Praxis Precision Medicines
PRAX
$8.58B
– –
-3,000
Closed -$12.4M
PRAX icon
167
PUT
Praxis Precision Medicines
PRAX
$8.58B
– –
-4,225
Closed -$17.5M
RAPT
168
CALL
DELISTED
RAPT Therapeutics
RAPT
– –
-250
Closed -$610K
SRPT icon
169
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-1,000
Closed -$15.8M
SRRK icon
170
Scholar Rock
SRRK
$5.67B
– –
-183,701
Closed -$1.61M
VKTX icon
171
Viking Therapeutics
VKTX
$3.7B
– –
-138,262
Closed -$7.33M
VRDN icon
172
PUT
Viridian Therapeutics
VRDN
$2.09B
– –
-2,789
Closed -$3.63M
VRNA
173
DELISTED
Verona Pharma
VRNA
– –
-201,116
Closed -$2.91M
QTTB icon
174
Q32 Bio
QTTB
$466M
– –
-109,094
Closed -$1.96M
GTHX
175
CALL
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-12,248
Closed -$2.79M
4 5 6
7
8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ikarian Capital held 176 positions worth $717M, up 25% from $574M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $179M of net new capital in Q3 2024, opening 63 new positions and adding to 14 existing holdings. Its largest new stake was BeOne Medicines Ltd: 88,167 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20.7M trimmed.

  • Ikarian Capital's largest Q3 2024 buy was BeOne Medicines Ltd: 88,167 shares worth $1.64M.
  • Ikarian Capital added most to Arcus Biosciences in Q3 2024, an estimated $9.44M increase.
  • Ikarian Capital's biggest Q3 2024 reduction was Sarepta Therapeutics, cutting an estimated $20.7M.
  • Ikarian Capital fully exited Immunovant in Q3 2024, selling an estimated $8.17M.
  • Ikarian Capital's ten largest holdings make up 43% of its $717M portfolio in Q3 2024.
  • Ikarian Capital opened 63 new positions and closed 31 in Q3 2024.
  • Ikarian Capital's portfolio value rose 25% quarter-over-quarter to $717M.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.